On Thursday, November 10th, Dr. Taube delivered her talk Multiplex IF Big Data, kicking off the session, Immuno-Oncology In The Age Of Multi-Omics: Translating Big Data Into Clinical Discoveries.
The following day, Dr. Taube spoke on the Pathologic Assessment of Tissues, Planning of Treatments, [and] Histopathology contributing to a session on Immunotherapy In Early Stage Disease.
Dr. Cottrell, who followed, shared research2 published earlier this November, in which the AstroPath team found further support for the findings from their and affiliates’ previous research on advanced melanoma1; the presence of the CD8+FoxP3+ subset of immune cell was indicative of a positive response to monoclonal antibody treatment as the first step in intervention, as well as overall clinical outcome.
- Berry, S., Giraldo, N. A., Green, B. F., Cottrell, T. R., … Taube, J. M., et al Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD1 blockade Science. 2021; 372, eaba2609.
- Cohen, E., Wang, D., Engle, E., et al (57) CD8+FoxP3+ cells represent early, effector T-cells and predict outcomes in patients with resectable non-small cell lung carcinoma (NSCLC) receiving neoadjuvant anti-PD-1-based therapy Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0057
